MagForce AG
· ISIN: DE000A0HGQF5
· EQS - adhoc news
Agreement in principle on the sale of business operations
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News MagForce AG
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
14 November 2022 09:08PM
Agreement in principle on the sale of business operations
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: Agreement in principle on the sale of business operations
Berlin, November 14, 2022 - The insolvency administrator of MagForce AG (ISIN: DE000A0HGQF5), Mr. Rüdiger Wienberg, attorney-at-law, today concluded the negotiations conducted with a...
MagForce AG
14 November 2022 09:08PM
MagForce AG: Agreement in principle on the sale of business operations
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: Agreement in principle on the sale of business operations
Berlin, November 14, 2022 - The insolvency administrator of MagForce AG (ISIN: DE000A0HGQF5), Mr. Rüdiger Wienberg, attorney-at-law, today concluded the negotiations conducted with a...
MagForce AG
27 October 2022 04:22PM
MagForce AG Decides to Delist its Shares
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG Decides to Delist its Shares
Berlin, October 27, 2022 - The Management Board of MagForce AG resolved to terminate the inclusion of the shares of MagForce AG (Frankfurt, Scale, ISIN: DE000A0HGQF5) in the over-the-counter segments Scale and B...
MagForce AG
27 October 2022 04:22PM
MagForce AG Decides to Delist its Shares
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG Decides to Delist its Shares
Berlin, October 27, 2022 - The Management Board of MagForce AG resolved to terminate the inclusion of the shares of MagForce AG (Frankfurt, Scale, ISIN: DE000A0HGQF5) in the over-the-counter segments Scale and B...
MagForce AG
06 October 2022 12:32PM
Opening of Insolvency Proceedings
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: Opening of Insolvency Proceedings
Berlin, October 6, 2022 – MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5) ) announces the opening of insolvency proceedings against its assets.
By order of the Berlin-Charlottenburg Local Co...
MagForce AG
06 October 2022 12:32PM
MagForce AG: Opening of Insolvency Proceedings
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: Opening of Insolvency Proceedings
Berlin, October 6, 2022 – MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5) ) announces the opening of insolvency proceedings against its assets.
By order of the Berlin-Charlottenburg Local Co...
MagForce AG
27 July 2022 08:30PM
Provisional insolvency administrator appointed by the court
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: Provisional insolvency administrator appointed by the court
Berlin, July 27, 2022 – MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5) informs that Mr. Rüdiger Wienberg of the law firm hww hermann wienberg wilhelm Insolvenzverwa...
MagForce AG
27 July 2022 08:30PM
MagForce AG: Provisional insolvency administrator appointed by the court
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: Provisional insolvency administrator appointed by the court
Berlin, July 27, 2022 – MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5) informs that Mr. Rüdiger Wienberg of the law firm hww hermann wienberg wilhelm Insolvenzverwa...
MagForce AG
26 July 2022 07:05PM
Application for the Opening of Insolvency Proceedings
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: Application for the Opening of Insolvency Proceedings
Berlin, July 26, 2022 – Today, the Management Board of MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), in consultation with the Supervisory Board, decided, to file an app...
MagForce AG
26 July 2022 07:05PM
MagForce AG: Application for the Opening of Insolvency Proceedings
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: Application for the Opening of Insolvency Proceedings
Berlin, July 26, 2022 – Today, the Management Board of MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), in consultation with the Supervisory Board, decided, to file an app...
MagForce AG
30 June 2022 08:30AM
MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights
MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights
MagForce USA received approval by the Centers for Medicare and Medicaid Services (CMS) to cover the majority of treatment-related costs in the ongoing clinical trial in the US after commercial payment code approval from the American Medical Association (AM...
MagForce AG
30 June 2022 08:30AM
MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights
MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights
MagForce USA received approval by the Centers for Medicare and Medicaid Services (CMS) to cover the majority of treatment-related costs in the ongoing clinical trial in the US after commercial payment code approval from the American Medical Association (AM...
MagForce AG
25 June 2022 11:40AM
MagForce AG issues Bearer Notes with a total Volume of up to EUR 3.5 Million to Lansdowne Investment Company Cyprus Limited
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG issues Bearer Notes with a total Volume of up to EUR 3.5 Million to Lansdowne Investment Company Cyprus Limited
Berlin, June 25, 2022 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the ...
MagForce AG
25 June 2022 11:40AM
MagForce AG issues Bearer Notes with a total Volume of up to EUR 3.5 Million to Lansdowne Investment Company Cyprus Limited
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG issues Bearer Notes with a total Volume of up to EUR 3.5 Million to Lansdowne Investment Company Cyprus Limited
Berlin, June 25, 2022 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the ...
MagForce AG
08 April 2022 09:00AM
MagForce AG: MagForce USA, Inc. receives Payment Code Approval by the American Medical Association for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
MagForce AG: MagForce USA, Inc. receives Payment Code Approval by the American Medical Association for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Category III CPT codes will ensure seamless billing and tracking process for payers already at the time FDA marketing approval is secured
NanoTherm Therapy CPT codes will ...
MagForce AG
25 February 2022 10:19PM
MagForce AG extends EUR 5.0 million Convertible Notes agreement with Lansdowne Investment Company Cyprus Limited and issues additional Convertible Notes in the amount of EUR 2.0 million
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG extends EUR 5.0 million Convertible Notes agreement with Lansdowne Investment Company Cyprus Limited and issues additional Convertible Notes in the amount of EUR 2.0 million
Berlin, February 25, 2022 - MagForce AG (Frankfurt, Scale, Xetra: M...
MagForce AG
20 December 2021 08:30AM
MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval
MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval
Stage 2b of the single arm study will enroll up to 100 men who have progressed to intermediate risk prostate cancer stage and are under active surveillance
First p...
MagForce AG
05 November 2021 11:51AM
MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Ther
MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Following FDA green-light, Stage 2b of the pivotal trial will begin immediately
Patient screening and enrollment will be expedited and,...
MagForce AG
05 November 2021 10:48AM
MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Ther
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Following FDA greenlight, Stage 2b of the ...
MagForce AG
28 October 2021 08:30AM
MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights
MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights
- Europe: Significant upward trend - both in patient numbers and in the number of centers in Europe offering NanoTherm therapy
- USA: Stage 2a of pivotal single-arm study for the focal ablation of intermediate risk prostate cancer successfully completed - Stage 2b with f...
MagForce AG
13 October 2021 08:30AM
MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Berlin, Germany and Nevada, USA, October 13, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company i...
MagForce AG
30 September 2021 08:00AM
MagForce AG and CHIP Hospital Málaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain agForce AG:
MagForce AG and CHIP Hospital Málaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain
- Complejo Hospitalario Integral Privado (CHIP) will be first clinic in Spain to offer MagForce's technology for the commercial treatment of brain cancer patients
- Additio...
MagForce AG
12 August 2021 05:15PM
MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board
MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board
Berlin, Germany, and Nevada, USA, August 12, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the results of the 2021 Annual Gener...
MagForce AG
30 June 2021 08:30AM
MagForce AG Publishes Financial Results for the Year 2020 and Operative Highlights
MagForce AG Publishes Financial Results for the Year 2020 and Operative Highlights
- Europe: High growth in treatment numbers beginning of 2020 - after severe COVID-19 impact European roll-out now picks up speed again
- USA: Stage 2a of pivotal single-arm study for the focal ablation of intermediate risk prostate cancer completed - additional dat...
MagForce AG
07 June 2021 08:30AM
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications
Berlin, Germany, and Nevada, USA, June 7, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, o...
MagForce AG
26 April 2021 08:45AM
MagForce AG Announces Additional Supportive Data from Stage 2a of its Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System
MagForce Announces Additional Supportive Data from Stage 2a of its Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System
- Further analysis of the Stage 2a results confirm positive initial findings published in February of this year - treatment-related side effects remained min...
MagForce AG
15 December 2020 01:20PM
MagForce AG Successfully Completes Private Placement of New Shares
MagForce AG Successfully Completes Private Placement of New Shares
- Placement of 1.165 million shares or 4.2 percent of the share capital
- Gross proceeds of approx. EUR 4.7 million
Berlin and Nevada, December 15, 2020 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedici...
MagForce AG
15 December 2020 01:17PM
MagForce AG Successfully Places 1,165 Million New Shares Through Cash Capital Increase with Gross Proceeds of approx. 4.7 Million EUR
Publication of Inside Information according to Article 17 MAR
MagForce AG Successfully Places 1,165 Million New Shares Through Cash Capital Increase with Gross Proceeds of approx. 4.7 Million EUR
NOT FOR DIRECT OR INDIRECT DISTRIBUTION OR PUBLICATION IN THE USA OR IN OR INTO CANADA, AUSTRALIA OR JAPAN OR OTHER COUNTRIES WHERE SUCH DISTRIBUTION OR...
MagForce AG
10 December 2020 05:46PM
MagForce AG Launches Capital Increase with Exclusion of Subscription Rights from Authorized Capital
Publication of Inside Information according to Article 17 MAR
MagForce AG Launches Capital Increase with Exclusion of Subscription Rights from Authorized Capital
NOT FOR DIRECT OR INDIRECT DISTRIBUTION OR PUBLICATION IN THE USA OR IN OR INTO CANADA, AUSTRALIA OR JAPAN OR OTHER COUNTRIES WHERE SUCH DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL
B...
MagForce AG
08 December 2020 08:30AM
MagForce AG Announces Opening of New NanoTherm Treatment Center for Brain Tumor Patients at Mühlhausen Hufeland Clinic in Thuringia, Germany
MagForce AG Announces Opening of New NanoTherm Treatment Center for Brain Tumor Patients at Mühlhausen Hufeland Clinic in Thuringia, Germany
All audits of the new NanoTherm treatment center at the Mühlhausen Hufeland Clinic have been completed, first patients are anticipated to be treated in December 2020
The center is managed by PD Dr. Johannes ...
MagForce AG
30 October 2020 08:30AM
MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights
MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights
- Very significant increase in European patient inquiries for NanoTherm therapy system for the treatment of glioblastomas
- U.S. focal prostate cancer treatment study: positive findings of Stage 1 confirmed during current Stage - positive treatment resul...
MagForce AG
20 October 2020 09:50AM
'NanoTherm School' successfully enters the third round with 'Module B - Part II'
DGAP-Media / 20.10.2020 / 09:50
MagForce AG: 'NanoTherm School' successfully enters the third round with 'Module B - Part II'
- MagForce successfully hosted the third session of the practice-oriented, unique and multifaceted application training series for the use of the NanoTherm therapy system for the treatment of glioblastoma.
- The Nan...
MagForce AG
21 September 2020 08:45AM
MagForce AG Publishes Shareholder Letter
MagForce AG Publishes Shareholder Letter
Europe: Continued significantly increased numbers of brain tumor treatments
USA: Treatments of patients in current stage of the prostate cancer trial with streamlined protocol so far show only minimal treatment-related side effects
Berlin, Germany, and Nevada, USA, September 21, 2020 - MagForce AG (Frankf...
MagForce AG
13 August 2020 03:00PM
MagForce AG announces positive results of 2020 Annual General Meeting
MagForce AG announces positive results of 2020 Annual General Meeting
Berlin, Germany, and Nevada, USA, August 13, 2020 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, held its Annual General Meeting today in a virtual setting. The Annual General M...
MagForce AG
More MagForce AG related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 12 | 27th July 2022 | EQS Group AG | Corporate Research |
| Directors Dealings | 0 | - | - | DD |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN